Dr. Pamela Munster graduated from the University of Bern Faculty of Medicine. She did her residency program at the Indiana University School of Medicine and also completed a fellowship at the Memorial Sloan-Kettering Cancer Center. She is a board-certified medical oncologist and currently practices at the UCSF Medical Center and San Francisco General Hospital, San Francisco, California. She has also contributed to several research publications.
University of Bern Faculty of Medicine
Indiana University School of Medicine
Memorial Sloan-Kettering Cancer Center
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
Thomas, S.,Aggarwal, R.,Jahan, T.,Ryan, C.,Troung, T.,Moore Cripps, A.,Raha, P.,Thurn, K. T.,Chen, S.,Grabowsky, J. A.,Park, J.,Hwang, J.,Daud, A.,Munster, P. N.; Ann. Oncol.. 2016 Feb 24.See more >>
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.
Chien, A. J.,Cockerill, A.,Fancourt, C.,Schmidt, E.,Moasser, M. M.,Rugo, H. S.,Melisko, M. E.,Ko, A. H.,Kelley, R. K.,Korn, W. M.,Esserman, L. J.,Van't Veer, L.,Yau, C...; Breast Cancer Res. Treat.. 2016 Feb 15.See more >>
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha, P.,Thomas, S.,Thurn, K. T.,Park, J.,Munster, P. N.; Breast Cancer Res.. 2015 Mar 18.See more >>